OCC 2.92% 66.5¢ orthocell limited

I did say "study" not trial, but do stand corrected. 72...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,895 Posts.
    lightbulb Created with Sketch. 7130

    I did say "study" not trial, but do stand corrected. 72 controlled "cases" is certainly not necessarily patients, more likely animal cases despite the company often pointing to data/reports from human cases outside of and before clinical trials (special access scheme, etc). 3Q 20 reports will reveal, but being pre-clinical, more likely non-human. My apologies.

    The original company release should be what everyone relies on, not my or others comments (DYOR, etc):

    https://www.orthocell.com.au/asx-announcements-3

    Again, page 8 down the bottom, 'Postive CelGro Study Results in ACL Reconstruction'.


 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
66.5¢
Change
-0.020(2.92%)
Mkt cap ! $159.0M
Open High Low Value Volume
67.0¢ 67.0¢ 65.0¢ $245.7K 371.8K

Buyers (Bids)

No. Vol. Price($)
2 15000 65.5¢
 

Sellers (Offers)

Price($) Vol. No.
66.5¢ 12621 2
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.